IDH1 and oligodendroglioma: Therefore, peptide-based vaccines have been the most extensively investigated vaccines, and current research on vaccine-based immunotherapy for oligodendrogliomas has predominantly focused on peptide vaccines, partially owing to their well-defined antigenic targets (e.g., IDH1-R132H neoantigens) and manageable safety profiles [1,98].